

Please type a plus sign (+) inside this box



#6

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 7

Application Number 09/658,537
Filing Date September 9, 2000
First Named Inventor Paton, Adrienne W.
Group Art Unit 1631
Examiner Name
Attorney Docket Number 019957-014500US

TECH CENTER 1631/2900

SEP 13 2001

RECEIVED

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document Number Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US 4,698,332	Ogasawara, et al.	10-06-1987	
	AB	US 5,032,519	Paulson, et al.	07-16-1991	
	AC	US 5,089,479	Krivan, et al.	02-18-1992	
	AD	US 5,260,380	Isayev, Avraam	11-09-1993	
	AE	US 5,401,723	Gaffar, et al.	03-28-1995	
	AF	US 5,514,660	Zopf, et al.	05-07-1996	
	AG	US 5,576,306	Ratcliffe, Robert M.	11-19-1996	
	AH	US 5,614,374	Adachi, et al.	05-25-1997	
	AI	US 5,627,163	Heerze, et al.	05-06-1997	
	AJ	US 5,696,000	Krivan, et al.	12-09-1997	
	AK	US 5,753,631	Paulson, et al.	06-19-1998	
	AL	US 5,736,533	Simon, et al.	04-07-1998	
	AM	US 5,811,404	De Frees, et al.	09-22-1998	
	AN	US 5,849,714	Rafter, et al.	12-15-1998	
	AO	US 5,955,347	Lowe, John B.	08-21-1999	
	AP	US 6,069,137	Heerze, et al.	05-30-2000	

FOREIGN PATENT DOCUMENTS

Examiner Signature	Ba / H	Date Considered	5/7/01
--------------------	--------	-----------------	--------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1254435 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number 09/658,537
Filing Date September 9, 2000
First Named Inventor Paton, Adrienne W.
Group Art Unit 1635
Examiner Name
Attorney Docket Number 019957-014500US

TECH CENTER 1600/2900

SEP 13 2001

RECEIVED

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
DW	AQ	EPO	WO 95/33467	A2	The Rockefeller University	12-14-1995		<input type="checkbox"/>
	AR	EPO	WO 96/40169	A1	Neose Technologies, Inc.	12-19-1996		<input type="checkbox"/>
	AS	EPO	WO 97/03701	A2	Glycotech Corp.	02-06-1997		<input type="checkbox"/>
	AT	EPO	WO 98/14215	Abstract only A2	Syntosome Gesellschaft Fur Med. Biochemie M.B.H.	04-09-1998		<input type="checkbox"/>
	AU	EPO	WO 99/56754	A1	Abbott Laboratories	11-11-1999		<input type="checkbox"/>
	AV	JP	2268129	Abstract only A	SANKO CHEM CO LTD	01-11-1990		<input type="checkbox"/>
	AW	JP	7258093	A	MORINAGA MILK IND CO LTD	10-09-1995		<input type="checkbox"/>
	AX	JP	9315981	A	SNOW BRAND MILK PROD CO LTD	12-09-1997		<input type="checkbox"/>
DW	AY	JP	10- 029945	A	SNOW BRAND MILK PROD CO LTD	02-03-1998		<input type="checkbox"/>
								<input type="checkbox"/>

Examiner
Signature

[Handwritten Signature]

Date
Considered

5/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
SF 1254435 v1

Please type a plus sign (+) inside this box → +



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 7

Complete if Known

Application Number	09/658,537
Filing Date	September 9, 2000
First Named Inventor	Paton, Adrienne W.
Group Art Unit	1635
Examiner Name	
Attorney Docket Number	019957-014500US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DN	AZ	Annaix, et al. "Structures Involved in the Binding of Human Fibrinogen to <i>Candida albicans</i> Germ Tubes" <i>FEMS Microbiology Immunology</i> , (1990) Vol. 64, pp. 147-154.	<input type="checkbox"/>
	AAA	Armstrong, et al. "Clinical Trials of Synsorb-Pk in Preventing Hemolytic-Uremic Syndrome" Kaper O Brien eds <i>Escherichia coli</i> O157:H7 and other Shiga Toxin-Producing <i>E. coli</i> Strains. American Society for Microbiology, Washington, D.C. (1998) pp. 374-84.	<input type="checkbox"/>
	AAB	Armstrong, et al. "Investigation of Shiga-like Toxin Binding to Chemically Synthesized Oligosaccharide Sequences" <i>J. Infect. Dis.</i> (1991) Vol. 164, pp. 1160-1167.	<input type="checkbox"/>
	AAC	Barra, et al. "Escherichia coli Heat-labile Enterotoxin Preferentially Interacts with Blood Group A-active Glycolipids From Pig Intestinal Mucosa and A- and B-active Glycolipids From Human Red Cells Compared to H-active Glycolipids" <i>Molecular and Cellular Biochemistry</i> , (1992) Vol. 115, pp. 63-70.	<input type="checkbox"/>
	AAD	Bauer, et al. "Genetic and Structural Analysis of a Virulence Determinant in Polymavirus VP1" <i>Journal of Virology</i> (December 1995) Vol. 69(12), pp. 7925-7931.	<input type="checkbox"/>
	AAE	Bouchara, et al. "Sialic Acid-Dependent Recognition of Laminin and Fibrinogen by <i>Aspergillus fumigatus</i> Conidia" <i>Infection and Immunity</i> (July 1997), Vol. 65(7), pp. 2717-2724.	<input type="checkbox"/>
	AAF	Brown, et al. "Erythrocyte P Antigen: Cellular Receptor for B19 Parvovirus" <i>Science</i> (October 1993) Vol. 262, pp.114-117.	<input type="checkbox"/>
	AAG	Cameron, et al. "Blood Group Glycolipids as Epithelial Cell Receptors for <i>Candida albicans</i> " <i>Infection and Immunity</i> (March 1996) Vol. 64(3), pp. 891-896.	<input type="checkbox"/>
	AAH	Cao, et al. "Role of Carbohydrate-mediated Adherence in Cytopathogenic Mechanisms of <i>Acanthamoeba</i> " <i>The Journal of Biological Chemistry</i> (June 1998) Vol. 273(25), pp. 15838-15845.	<input type="checkbox"/>
	AAI	Connor, et al. "Receptor Specificity in Human, Avian, and Equine H2 and H3 Influenza Virus Isolates" <i>Virology</i> (1994) Vol. 205, pp. 17-23.	<input type="checkbox"/>
DL	AAJ	"Critchley, et al. "Role of Glycosides as Epithelial Cell Receptors for <i>Candida albicans</i> " <i>J. of General Microbiology</i> (1987) Vol. 133, pp. 637-643.	<input type="checkbox"/>

Examiner Signature

[Signature]

Date Considered

5/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1254435 v1

SEP 13 2001

RECEIVED

TECH CENTER 1600/2900

Please type a plus sign (+) inside this box →

+

SEP 10 2001

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 7

Complete if Known

Application Number 09/658,537
Filing Date September 9, 2000
First Named Inventor Paton, Adrienne W.
Group Art Unit 1635
Examiner Name
Attorney Docket Number 019957-014500US

TECH CENTER 1600/2900

SEP 13 2001

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BW	AAK	Crocker, et al. "The Potential Role of Sialoadhesin as a Macrophage Recognition Molecule in Health and Disease" <i>Glycoconjugate Journal</i> (1997) Vol. 14, pp. 601-609.	<input type="checkbox"/>
	AAL	Donnelly, et al. "Blocking Bacterial Enterotoxins" <i>Nature Medicine</i> , (March 2000), Vol. 6 (3), pp. 257-258.	<input type="checkbox"/>
	AAM	Eisen, et al. "Binding of the Influenza A Virus to Cell-Surface Receptors: Structures of Five Hemagglutinin-Sialyoligosaccharide Complexes Determined by X-ray Crystallography" <i>Virology</i> (1997) Vol. 232, pp. 19-31.	<input type="checkbox"/>
	AAN	Falk, et al. "An in vitro Adherence Assay Reveals that <i>Helicobacter pylori</i> Exhibits Cell Lineage-specific Tropism in the Human Gastric Epithelium" <i>Proc. Natl. Acad. Sci. USA</i> (March 1993) Vol. 90, pp. 2035-2039.	<input type="checkbox"/>
	AAO	Frank, et al. "Comparison of the Conformational Behavior of Sialyllactose Complexed with the two Viral Attachment Proteins Influenza A Hemagglutinin and the Murine Polymavirus" <i>J. Mol. Model</i> (1997) Vol. 3, pp. 408-414.	<input type="checkbox"/>
	AAP	Gambaryan, et al. "Specification of Receptor-Binding Phenotypes of Influenza Virus Isolates from Different Hosts Using Synthetic Sialylglycopolymers: Non-Egg-Adapted Human H1 and H3 Influenza A and Influenza B Viruses Share a Common High Binding Affinity for 6' Sialyl(N-acetyl)lactosamine" <i>Virology</i> (1997) Vol. 232, pp. 345-350.	<input type="checkbox"/>
	AAQ	Herrler, et al. "The Surface Receptor is a Major Determinant of the Cell Tropism of Influenza C Virus" <i>Virology</i> (1987) Vol. 159, pp. 102-108.	<input type="checkbox"/>
	AAR	Idänpään-Heikkilä, et al. "Oligosaccharides Interfere with the Establishment and Progression of Experimental Pneumococcal Pneumonia" <i>J. of Infectious Diseases</i> (1997) Vol. 176, pp. 704-12.	<input type="checkbox"/>
	AAS	Idota, et al. "Growth-promoting Effects of N-Acetylneuraminic Acid-containing Substances on Bifidobacteria" <i>Biosci. Biotech. Biochem.</i> (1994) Vol. 58(9), pp. 1720-1722.	<input type="checkbox"/>
	AAT	Idota, et al. "Inhibition of Cholera Toxin by Human Milk Fractions and Sialyllactose", <i>Biosci. Biotech. Biochem.</i> (1995) Vol. 59(3) pp. 417-419.	<input type="checkbox"/>
PL	AAU	Johnson, et al. "Synthesis of Oligosaccharides by Bacterial Enzymes" <i>Glycoconjugate Journal</i> , 1999, Vol. 16, pp. 141-146.	<input type="checkbox"/>

Examiner Signature

B. A. 2/1/01

Date

Considered

5/7/02


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1254435 v1

Please type a plus sign (+) inside this box →

+



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 7

Complete if Known

Application Number	09/658,537
Filing Date	September 9, 2000
First Named Inventor	Paton, Adrienne W.
Group Art Unit	1635
Examiner Name	
Attorney Docket Number	019957-014500US

TECH CENTER
SEP 13 2001

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BW	AAV	Klemm, <i>et al.</i> "A Stochastic Killing System for Biological Containment of <i>Escherichia coli</i> " <i>Applied and Environmental Microbiology</i> (February 1995), Vol. 61(2), pp. 481-486.	<input type="checkbox"/>
	AAW	Klenk, <i>et al.</i> "Carbohydrate-Mediated Adhesion of Viruses" <i>Nova Acta Leopoldina NF</i> (1997) Vol. 75(301), pp. 131-142.	<input type="checkbox"/>
	AAX	Koeller, <i>et al.</i> "Tyrosine Sulfation on a PSGL-1 Glycopeptide Influences the Reactivity of Glycosyltransferases Responsible for Synthesis of the Attached O-Glycan" <i>J. Am. Chem. Soc.</i> (2000) Vol. 122, pp. 742-743.	<input type="checkbox"/>
	AAV	Krivan, <i>et al.</i> "Many Pulmonary Pathogenic Bacteria Bind Specifically to the Carbohydrate Sequence (GalNAcB1-4Gal) Found in Some Glycolipids" <i>Proc. Natl. Acad. Sci. USA</i> (1998) Vol. 85 pp. 6157-6161.	<input type="checkbox"/>
	AAZ	Kuo, <i>et al.</i> "An N-linked High-mannose Type Oligosaccharide, Expressed at the Major Outer Membrane Protein of <i>Chlamydia trachomatis</i> , Mediates Attachment and Infectivity of the Microorganism to HeLa Cells" <i>J. Clin. Invest.</i> (December 1996) Vol. 98(12), pp. 2813-2818.	<input type="checkbox"/>
	AAAA	Lanne, <i>et al.</i> "Enhanced Binding of Enterotoxigenic <i>Escherichia coli</i> K99 to Amide Derivatives of the Receptor Ganglioside NeuGc-GM ₃ " <i>Biochemistry</i> (1995) Vol. 34, pp. 1845-1850.	<input type="checkbox"/>
	AAAB	Levine, <i>et al.</i> "Recombinant DNA Risk Assessment Studies in Humans: Efficacy of Poorly Mobilizable Plasmids in Biologic Containment" <i>J. of Infectious Diseases</i> (October 1983), Vol. 148(4), pp. 699-709.	<input type="checkbox"/>
	AAAC	Matei, <i>et al.</i> "Isolation of Natural Fucose-containing Saccharides and Preliminary Data on Their Effectiveness in Inhibition of <i>Candida albicans</i> Adherence to Human Buccal Epithelial Cells" <i>Rev. roum. Biochim</i> (1997) Vol. 34, pp. 123-130.	<input type="checkbox"/>
	AAAD	May, <i>et al.</i> "Expression, Crystallization, and Preliminary X-ray Analysis of a Sialic Acid-binding Fragment of Sialoadhesin in the Presence and Absence of Ligand" <i>Protein Science</i> (1997) Vol. 6, pp. 717-721.	<input type="checkbox"/>
BW	AAAE	Neeser, <i>et al.</i> "A 23 kDa Membrane Glycoprotein Bearing (NeuNAc2-3GalB1-3)GalNAc O-linked Carbohydrate Chains Acts as a Receptor for <i>Streptococcus sanguis</i> Omz 9 on Human Buccal Epithelial Cells" <i>Glycobiology</i> (1995) Vol. 5(1), pp. 97-104.	<input type="checkbox"/>

Examiner Signature

BW

Date

Considered

5/7/02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SF 1254435 v1

Please type a plus sign (+) inside this box →

+



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 7

Complete if Known

Application Number	09/658,537
Filing Date	September 9, 2000
First Named Inventor	Paton, Adrienne W.
Group Art Unit	1635
Examiner Name	
Attorney Docket Number	019957-014500US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DK	AAAF	Newburg, David S. "Do the Binding Properties of Oligosaccharides in Milk Protect Human Infants from Gastrointestinal Bacteria" <i>Symposium: Bioactive Components in Milk and Development of the Neonate: Does Their Absence Make a Difference, presented by The American Society for Nutritional Studies.</i> (1997) pp. 980S-984S.	<input type="checkbox"/>
	AAAG	Paton, et al. "A New Biological Agent for Treatment of Shiga Toxigenic Escherichia coli Infections and Dysentery in Humans" <i>Nature Medicine</i> (March 2000) Vol. 6(3), pp. 265-270.	<input type="checkbox"/>
	AAAH	Phillips, et al. "Characterization of Chimeric Lipopolysaccharides from Escherichia coli Strain JM109 Transformed with Lipooligosaccharide Synthesis Genes (lsg) from Haemophilus influenzae" <i>J. Biol. Chem USA</i> , 2000, Vol. 257 (7), pp. 4747-4758.	<input type="checkbox"/>
	AAAI	Reyes-Leyva, et al. "The Porcine Paramyxovirus LPM Specifically Recognizes Sialyl (a 2,3) Lactose-containing Structures" <i>Arch Virol</i> (1993) Vol. 133, pp. 195-200.	<input type="checkbox"/>
	AAAJ	Roberts, et al. "Sialic Acid-dependent Adhesion of <i>Mycoplasma pneumoniae</i> to Purified Glycoproteins" <i>J. of Biological Chemistry</i> (June 1989) Vol. 264(16), pp. 9289-9293.	<input type="checkbox"/>
	AAAK	"Schwertmann, et al. "S-Fimbriae From <i>Escherichia coli</i> Bind to Soluble Glycoproteins From Human Milk" <i>J. of Pediatric Gastroenterology and Nutrition</i> (March 1999) Vol. 28, pp. 257-263.	<input type="checkbox"/>
	AAAL	Sjöberg, et al. "Purification and Characterization of CS2, a Sialic Acid-specific Haemagglutinin of Enterotoxigenic <i>Escherichia coli</i> " <i>Biochem J.</i> (1988) Vol. 255, pp. 105-111.	<input type="checkbox"/>
	AAAM	Stehle, et al. "Crystal Structures of Murine Polyomavirus in Complex with Straight-chain and Branched-chain Sialyloligosaccharide Receptor Fragments" <i>Structure</i> (1996) Vol. 4(2), pp. 183-194.	<input type="checkbox"/>
DK	AAAN	Taiyo, Kaguki, "Sialyloligosaccharides from Egg Yolk as an Inhibitor of Rotaviral Infection" <i>J. Agric. Food Chem.</i> (1995) Vol. 43, pp. 858-861.	<input type="checkbox"/>

Examiner Signature

[Signature]

Date Considered

5/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1254435 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 7

Complete if Known

Application Number 09/658,537
Filing Date September 9, 2000
First Named Inventor Paton, Adrienne W.
Group Art Unit 1635
Examiner Name
Attorney Docket Number 019957-014500US

TECH CENTER 1600/2900

SEP 13 2001

RECEIVED

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
PW	AAAO	Takeda, <i>et al.</i> "In Vitro Assessment of a Chemically Synthesized Shiga Toxin Receptor Analog Attached to Chromosorb P (Synsorb Pk) as a Specific Absorbing Agent of Shiga Toxin 1 and 2" <i>Microbiol. Immunol.</i> (1999), Vol. 43 (4), pp. 331-337.	<input type="checkbox"/>
	AAAP	Tokojenko, <i>et al.</i> <i>Microbiol. Zhr.</i> (1994) Vol. 56(4), pp. 3-9. examiner does speak and/or read this language	<input type="checkbox"/>
DL	AAAQ	van Alphen, <i>et al.</i> "Blocking of Fimbria-Mediated Adherence of <i>Haemophilus influenzae</i> by Sialyl Gangliosides" <i>Infection and Immunity</i> (December 1991) Vol. 59(12), pp. 4473-4477.	<input type="checkbox"/>
DL	AAAR	Willemsen, <i>et al.</i> "Multivalent Binding of K99 Fimbriae to the N-Glycolyl-GM ₃ Ganglioside Receptor" <i>Infection and Immunity</i> (October 1993) Vol. 61(10), pp. 4518-4522.	<input type="checkbox"/>
pr	AAAS	Yan, <i>et al.</i> "Determination of GDP-Fuc:Galβ1-4GlcNAc-R (Fuc to GlcNAc) α 1,3 Fucosyltransferase Activity by a Solid-Phase Method" <i>Analytical Biochemistry</i> (1994) Vol. 223, pp. 111-118.	<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>
			<input type="checkbox"/>

Examiner Signature

[Handwritten Signature]

Date Considered

5/7/02

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
SF 1254435 v1